Loading
PDBj
メニューPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

2G49

Crystal structure of human insulin-degrading enzyme in complex with glucagon

2G49 の概要
エントリーDOI10.2210/pdb2g49/pdb
関連するPDBエントリー2G47 2G48 2G54 2G56
分子名称Insulin-degrading enzyme, glucagon preproprotein, 1,4-DIETHYLENE DIOXIDE, ... (4 entities in total)
機能のキーワードprotein-peptide complex, hydrolase
由来する生物種Homo sapiens (human)
詳細
タンパク質・核酸の鎖数4
化学式量合計236580.05
構造登録者
Shen, Y.,Tang, W.-J. (登録日: 2006-02-21, 公開日: 2006-10-24, 最終更新日: 2024-02-14)
主引用文献Shen, Y.,Joachimiak, A.,Rosner, M.R.,Tang, W.J.
Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism.
Nature, 443:870-874, 2006
Cited by
PubMed Abstract: Insulin-degrading enzyme (IDE), a Zn2+-metalloprotease, is involved in the clearance of insulin and amyloid-beta (refs 1-3). Loss-of-function mutations of IDE in rodents cause glucose intolerance and cerebral accumulation of amyloid-beta, whereas enhanced IDE activity effectively reduces brain amyloid-beta (refs 4-7). Here we report structures of human IDE in complex with four substrates (insulin B chain, amyloid-beta peptide (1-40), amylin and glucagon). The amino- and carboxy-terminal domains of IDE (IDE-N and IDE-C, respectively) form an enclosed cage just large enough to encapsulate insulin. Extensive contacts between IDE-N and IDE-C keep the degradation chamber of IDE inaccessible to substrates. Repositioning of the IDE domains enables substrate access to the catalytic cavity. IDE uses size and charge distribution of the substrate-binding cavity selectively to entrap structurally diverse polypeptides. The enclosed substrate undergoes conformational changes to form beta-sheets with two discrete regions of IDE for its degradation. Consistent with this model, mutations disrupting the contacts between IDE-N and IDE-C increase IDE catalytic activity 40-fold. The molecular basis for substrate recognition and allosteric regulation of IDE could aid in designing IDE-based therapies to control cerebral amyloid-beta and blood sugar concentrations.
PubMed: 17051221
DOI: 10.1038/nature05143
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.5 Å)
構造検証レポート
Validation report summary of 2g49
検証レポート(詳細版)ダウンロードをダウンロード

226707

件を2024-10-30に公開中

PDB statisticsPDBj update infoContact PDBjnumon